Related Experiment Video
Updated: Dec 23, 2025

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
Sharing of Individual Participant Data from Clinical Trials: General Comparison and HIV Use Case
Craig S Mayer1,2, Nick Williams1,2, Sigfried Gold1
1Lister Hill National Center for Biomedical Communication, National Library of Medicine, NIH Bethesda, MD.
Abstract:
Sharing of individual participant data is encouraged by the International Committee of Medical Journal Editors. We analyzed clinical trial registry data from ClinicalTrials.gov (CTG) and determined the proportion of trials sharing de-identified Individual Participant Data (IPD). We looked at 3,138 medical conditions (as Medical Subject Heading terms). Overall, 10.8% of trials with first registration date after December 1, 2015 answered 'Yes' to plan to share de-identified IPD data. This sharing rate ranges between 0% (biliary tract neoplasms) to 72.2% (meningitis, meningococcal) when analyzed by disease that is focus of a study. Via a predictive model, we found that studies that deposited basic summary results data to CTG results registry, large studies and phase 3 interventional studies are most likely to declare intent to share IPD data. As part of an HIV common data element analysis project, we further compared a body of HIV trials (24% sharing rate) to other diseases.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioavailability Study Design: Healthy Subjects Versus Patients
Hazard Ratio
For example, in a clinical trial...
Bioequivalence studies: Biowaivers
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

